MB, Levis & Associates’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Sell
2,928
-28
-0.9% -$9.59K 0.39% 35
2026
Q1
$1.04M Sell
2,956
-62
-2% -$22.1K 0.43% 35
2025
Q4
$988K Sell
3,018
-88
-3% -$27.9K 0.42% 33
2025
Q3
$876K Sell
3,106
-694
-18% -$201K 0.38% 34
2025
Q2
$1.06M Buy
3,800
+104
+3% +$29.5K 0.47% 35
2025
Q1
$1.15M Sell
3,696
-9
-0.2% -$2.66K 0.53% 34
2024
Q4
$966K Sell
3,705
-6
-0.2% -$1.78K 0.48% 37
2024
Q3
$1.2M Buy
3,711
+3
+0.1% +$981 0.59% 31
2024
Q2
$1.16M Buy
3,708
+28
+0.8% +$8.23K 0.61% 29
2024
Q1
$1.05M Buy
3,680
+25
+0.7% +$7.32K 0.56% 31
2023
Q4
$1.05M Buy
3,655
+12
+0.3% +$3.27K 0.6% 28
2023
Q3
$979K Sell
3,643
-16
-0.4% -$3.99K 0.63% 28
2023
Q2
$812K Buy
3,659
+2,288
+167% +$531K 0.52% 33
2023
Q1
$331K Buy
1,371
+8
+0.6% +$1.96K 0.23% 46
2022
Q4
$358K Buy
+1,363
New +$365K 0.28% 42

Other funds holding AMGN

MB, Levis & Associates's AMGN Position: Q2 2026 in Review

MB, Levis & Associates reduced its Amgen (AMGN) stake by 0.95% in Q2 2026, selling an estimated $9.59K and leaving 2,928 shares worth $1.06M. The position accounts for 0.39% of the portfolio, ranked #35.

MB, Levis & Associates first reported a position in AMGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.2M in Q3 2024. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • MB, Levis & Associates held 2,928 shares of Amgen worth $1.06M as of Q2 2026.
  • MB, Levis & Associates sold 28 Amgen shares in Q2 2026, an estimated $9.59K.
  • Amgen made up 0.39% of MB, Levis & Associates's portfolio in Q2 2026, its #35 holding.
  • MB, Levis & Associates first reported a position in Amgen in Q4 2022 and has held it in 15 quarters since.
  • MB, Levis & Associates's Amgen position peaked at $1.2M in Q3 2024.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.